Ticker Details
NovoCure Limited Ordinary Shares NovoCure Ltd is a medical systems developer in the United States. Its primary product is the TTFields delivery system, which is a low-intensity therapy to combat acute tumors.
IPO Date:	September 28, 2015
Sector:	Healthcare
Industry:	Medical Instruments and Supplies
Market Cap:	$1.27B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.28 | 2.69%
Avg Daily Range (30 D):	$0.40 | 3.16%
Avg Daily Range (90 D):	$0.34 | 2.66%

Institutional Daily Volume
Avg Daily Volume:	.81M
Avg Daily Volume (30 D):	1.8M
Avg Daily Volume (90 D):	1.45M

Trade Size
Avg Trade Size (Sh.):	72
Avg Trade Size (Sh.) (30 D):	69
Avg Trade Size (Sh.) (90 D):	68

Institutional Trades
Total Institutional Trades:	5,162
Avg Institutional Trade:	$3.58M
Avg Institutional Trade (30 D):	$2.36M
Avg Institutional Trade (90 D):	$2.68M
Avg Institutional Trade Volume:	.08M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$5.34M
Avg Closing Trade (30 D):	$2.35M
Avg Closing Trade (90 D):	$2.36M
Avg Closing Volume:	111.57K

News

Feb 17, 2026 @ 4:17 PM New Treatment Modalities Are Reaching Cancers That... Source: Prnewswire

Feb 13, 2026 @ 12:34 PM Soleus Adds a Significant Number of Celcuity Share... Source: Lawrence Rothman, Cfa

Feb 12, 2026 @ 5:57 PM FDA Approves First-of-Its-Kind Device to Treat Pan... Source: U.S. Food And Drug Administration

Feb 12, 2026 @ 1:31 PM Stock Market Today: Dow Jones, S&P 500 Futures Gai... Source: Rounak Jain

Sep 29, 2025 @ 8:30 PM Novocure to Present Final Results from the Pivotal... Source: Business Wire

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$-1.61	$-.33	$-.36
Diluted EPS	$-1.61	$-.33	$-.36
Revenue	$642.27M	$167.2M	$158.81M
Gross Profit	$484.08M	$122.48M	$117.33M
Net Income / Loss	$-177.65M	$-37.27M	$-40.14M
Operating Income / Loss	$-176.71M	$-36.02M	$-39.52M
Cost of Revenue	$158.19M	$44.73M	$41.47M
Net Cash Flow	$155.44M	$192.51M	$22.7M
PE Ratio